Brian Glass

2 months ago | triallawyernation.com | Michael Cowen |Brian Glass

The author of JuryBall: The Big Data Revolution is Here, Sean, joins Michael Cowen to discuss how using focus groups and big data have helped him learn from early losses and helped his clients get what they deserve. “Asking for too much money is dangerous, but if you don’t ask for enough money, you lose too,” says Sean.

May 31, 2024 | bioprocessonline.com | Brian Glass |Pharmatech Associates |Laura Walls

FOCUS ON PROCESS ENGINEERINGNovel technologies aren’t interesting to Rahul Kakkar, M.D. unless they help patients. Sounds rational, but it’s actually a unique perspective in a platform-crazed biotech industry. Dr. Kakkar’s worldview is shaped by his work as a physician — work he continues at Brigham and Women’s Hospital even as he builds Tome Biosciences, where he serves as President & CEO.

May 15, 2024 | cellandgene.com | Brian Glass |Pharmatech Associates

Genome editing holds immense promise for treating genetic diseases, but off-target effects remain a significant concern. To ensure the safety and efficacy of genome editing therapies, researchers are developing various strategies to reduce off-target effects. Register today for the next Cell & Gene Live. Attendance is free thanks to the support of Bio-Techne.

May 1, 2024 | cellandgene.com | Brian Glass |Pharmatech Associates

By Brian Glass, senior analytical consultant, Pharmatech Associates—a USP company Plasmid DNA (pDNA) is a biomolecule used in vaccines and gene therapies for many types of diseases. One of the basic requirements for materials used in the production of drug products is to assure that the materials are well characterized with respect to purity and impurity profiles of the materials.

Oct 3, 2023 | outsourcedpharma.com | Brian Glass |Pharmatech Associates |Louis Garguilo

By Brian Glass, Pharmatech Associates The International Council for Harmonization (ICH) and the United States Pharmacopoeia (USP) are currently finalizing draft guidelines that describe a new paradigm for analytical development based on the quality by design (QbD) approach used for pharmaceutical development. These guidelines describe the analytical life cycle management approach for the development, validation, and continuous monitoring of analytical procedures using QbD principles.